There’s no doubt about it: Xeljanz is causing some serious side effects. The drug’s negative impact on LDL cholesterol and lipids was warned about five years ago when Terry Graedon was a physician at the University of Toronto. It wasn’t until this new study, which was published in the New England Journal of Medicine, that the FDA mandated a new warning label for Xeljanz.
Announcing the Xeljanz Side Effects
Pfizer, the company that manufactures Xeljanz, was required to perform postmarketing studies on the drug, which the FDA mandated. The company sent a letter to health care providers alerting them to the new findings. Moreover, the drug’s manufacturers changed the dose, limiting it to 5 mg twice daily. However, the risks of blood clots are still a concern.
In addition to the risk of blood clots in the lungs, Xeljanz is also associated with the possibility of pulmonary embolism, which can have devastating consequences Xeljanz side effects. Hundreds of victims have filed Xeljanz lawsuits claiming that the drug company failed to properly warn patients about this potential risk. The new warnings state that patients should seek medical advice if they experience any of the side effects mentioned above.
Announcing the Xeljanz blood clot lawsuits is the first step in preventing these deadly outcomes from affecting the safety of the drug. This class action is aimed at preventing Pfizer from reducing its profits by changing the Xeljanz warnings. Plaintiffs hope to win the case by bringing their lawsuits against Pfizer.